Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice Miguel Mansilla-Polo, Antonio Sahuquillo-Torralba, Conrad Pujol-Marco, Guillermo Bargues-Navarro, Rafael Botella-Estrada

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil Tania F. Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V.E. Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M. Soliman, Tianshuang Wu, Ranjeeta Sinvhal, Vassilis Stakias, Alexandra P. Song, Jasmina Kalabic, Naomi Martin, Luiza Keiko Matsuka Oyafuso

Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab Francisco José Rodríguez-Cuadrado, Gaston Roustan-Gullón, Dolores Suárez-Massa, Mercedes Hospital-Gil